Danaher, a global science and technology innovator, completed the acquisition of Aldevron, a biotechnology company, from EQT Partners, a private equity firm, and TA Associates for $9.6bn. "For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster," Rainer Blair, Danaher President and CEO.